Prnewswire·2025-06-02 12:04Core Insights - Amgen's IMDELLTRA® (tarlatamab-dlle) has shown a 40% reduction in the risk of death and an increase in median overall survival by over five months compared to standard-of-care chemotherapy for small cell lung cancer patients who have progressed after platinum-based chemotherapy [1][3][5] Group 1: Clinical Trial Results - The Phase 3 DeLLphi-304 trial met its primary endpoint of overall survival (OS) and key secondary endpoint of progression-free survival (PFS) [2][5] - Median OS for IMDELLTRA was 13.6 months compared to 8.3 months for standard chemotherapy, with a hazard ratio of 0.60 [1][3] - Median PFS was also significantly improved for IMDELLTRA at 4.2 months versus 3.7 months for standard chemotherapy, with a hazard ratio of 0.71 [3][5] Group 2: Patient Outcomes - IMDELLTRA significantly improved patient-reported outcomes related to cancer symptoms such as dyspnea and cough compared to the control arm [2] - The safety profile of IMDELLTRA was consistent with known profiles, showing lower rates of grade 3 or higher treatment-related adverse events (TRAEs) at 27% compared to 62% in the control arm [4][5] Group 3: Mechanism and Indication - IMDELLTRA is a first-in-class targeted immunotherapy designed to bind to DLL3 on tumor cells and CD3 on T cells, activating T cells to kill DLL3-expressing SCLC cells [6][7] - It is indicated for adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have disease progression after platinum-based chemotherapy [7][8] Group 4: Industry Context - Small cell lung cancer (SCLC) is known for its aggressive nature, with a low five-year survival rate of 5-10% across all stages [8] - SCLC accounts for approximately 15% of the over 2.4 million lung cancer diagnoses globally each year [8]